Pulmonary surfactant in health and human lung diseases: State of the art

European Respiratory Journal

Volumn 13, Issue 6, 1999, Pages 1455-1476

  Griese, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Phosholipids; Surface activity; Surfactant protein B; Surfactant protein A; Surfactant protein C; Surfactant protein D

Indexed keywords

LIPID; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; SURFACTANT TA;

FORCED EXPIRATION; HUMAN; HYALINE MEMBRANE DISEASE; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEINOSIS; REVIEW;

HUMANS; LUNG; LUNG DISEASES; PULMONARY SURFACTANTS;

EID: 0032791063     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.13f36.x     Document Type: Review

References (216)

1. Robertson B, van Golde LG, Batenburg JJ. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam, Elsevier, 1992.
2. Johansson J, Curstedt T. Molecular structures and interactions of pulmonary surfactant components. Eur J Biochem 1997; 244: 675-693.
3. Crouch E. Collectins and pulmonary host defence. Am J Respir Cell Mol Biol 1998; 19: 177-210.
4. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77: 931-961.
5. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990; 259: L1-L12.
6. Griese M, Gobran LI, Rooney SA. Surfactant lipid uptake and secretion in type II cells in response to lectins and secretagogues. Am J Physiol 1991; 261: L434-L442.
7. Lu J, Willis C, Reid KM. Purification, characterisation and cDNA cloning of human lung surfactant protein D. Biochem J 1992; 284: 795-802.
8. Holmskov U, Lawson P, Teisner B, et al. Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein D binding molecule. J Biol Chem 1997; 272: 13743-13749.
9. Neergaard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik: die Retraktionskraft der Lunge, abhängig von der Oberflächenspannung in den Alveolen. Z Gesamte Exp Med 1929; 66: 373-394.
10. Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respir Physiol 1970; 8: 191-203.
11. Liu M, Wang L, Li E, Enhorning G. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 1991; 71: 742-748.
12. Enhorning C, Duffy LC, Welliver R. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995; 151: 554-556.
13. Enhorning G, Holm BA. Disruption of pulmonary surfactant's ability to maintain openness of a narrow tube. J Appl Physiol 1993; 74: 2922-2927.
14. Walters DD. The role of pulmonary surfactant in transepithelial movement of liquid. In: Robertson B, van Golde LG, Batenburg JJ, eds. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam, Elsevier, 1992; pp. 193-213.
15. Rooney SA, Young SL, Mendelson CR. Molecular and cellular processing of lung surfactant. FASEB J 1994; 8: 957-967.
16. Griese M, Gobran LI, Rooney SA. Signal-transduction mechanisms of ATP-stimulated phosphatidylcholine secretion in rat type II pneumocytes: interactions between ATP and other surfactant secretagogues. Biochim Biophys Acta 1993; 1167: 85-93.
17. Griese M, Gobran LI, Rooney SA. Ontogeny of surfactant secretion in type II pneumocytes from fetal newborn and adult rats. Am J Physiol 1992; 262: L337-L343.
18. Griese M, Dietrich P, Potz C, Westerburg B, Bals R, Reinhardt D. Surfactant subtractions during nosocomial infection in ventilated preterm human neonates. Am J Respir Crit Care Med 1996; 153: 398-403.
19. Baugham RP. The uncertainties of bronchoalveolar lavage. Eur Respir J 1997; 10: 1940-1942.
20. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1989; 2: 561-585.
21. Doyle IR, Davidson KG, Barr HA, Nicholas TE. Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis. Am J Respir Crit Care Med 1998; 157: 658-664.
22. Veldhuizen RW, Inchley K, Hearn SA, Lewis JF, Possmayer JF. Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem J 1993; 295: 141-147.
23. Griese M, Birrer P, Demirsoy A. Pulmonary surfactant in cystic fibrosis. Eur Respir J 1997; 10: 1983-1988.
24. Veldhuizen RW, McCaig L, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152: 1867-1871.
25. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153: 176-184.
26. King RJ, Clements JA. Surface active materials from dog lung. I. Method of isolation. Am J Physiol 1972; 223: 707-714.
27. Gross NJ, Narine KR. Surfactant subtypes in mice: characterization and quantitation. J Appl Physiol 1989; 66: 342-349.
28. Terao T, Tsuchihashi S, Yasuoka S. Biochemical analysis of airway aspirates of newborns. Tohoku J Exp Med 1996; 43: 69-77.
29. Griese M, Duroux A, Schams A, Lenz AG, Kleinasser N. Tracheobronchial surface active material in cystic fibrosis. Eur J Med Res 1997; 2: 114-120.
30. Hallman M, Arjomaa P, Tahvanainen J. Endobronchial surface active phospholipids in various pulmonary disease. Eur J Respir Dis 1985; 67: 37-47.
31. Darlow BA, Sluis KB, Inder TE, Winterbourn CC. Endotracheal suctioning of the neonate: comparison of two methods as a source of mucus material for research. Pediatr Res 1997; 23: 217-221.
32. Griese M, Potz C, Dietrich P, Westerburg B. Calcium, potassium, urea and total protein are not reliable dilutional markers of bronchoalveolar small volume-lavages in ventilated preterm human neonates. Eur J Med Res 1996; 1: 565-570.
33. Clements J. Smoking and pulmonary surfactant. N Engl J Med 1972; 286: 261-262.
34. Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patient with bacterial pneumonia. Am Rev Respir Dis 1993; 147: 653-657.
35. Clement A, Mashilah J, Housset B, et al. Decreased phosphatidyl choline content in bronchoalveolar lavage fluids of children with bronchopulmonary dysplasia. Pediatr Pulmonol 1987; 3: 67-70.
36. Begin R, Lesur O, Bouhadiba T, et al. Phospholipid content of bronchoalveolar lavage fluid in granite workers with silicosis in Quebec. Thorax 1993; 48: 840-844.
37. Escamilla R, Prevost MC, Cariven C, Hermant C, Krempf M. Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients. Eur Respir J 1993; 6: 1301-1307.
38. Gregory TJ, Longmore WJ, Moxley M, Whitsett JA, Reed CR, Fowler AA. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981.
39. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70: 673-683.
40. Honda Y, Tsunematsu K, Suzuki A, Akino T. Changes in phospholipids in bronchoalveolar lavage fluid of patients with interstitial lung disease. Lung 1988; 166: 293-301.
41. Honda Y, Kataoka K, Hayashi H, Takahashi H. Alterations of acidic phospholipids in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Clin Chim acta 1989; 181: 11-18.
42. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T. Surfactant protein A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103: 496-499.
43. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152: 1860-1866.
44. Honda Y, Takahashi H, Kuroki Y, Aktino T, Abe S. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996; 109: 1006-1009.
45. Hughes DA, Haslan PL, Path RC. Changes in phosphatidylglycerol in bronchoalveolar lavage fluids from patients with cryptogenic fibrosing alveolitis. Chest 1989; 95: 82-89.
46. Hughes DA, Haslam PL. Effect of smoking on the lipid composition of lung lining fluid and relationship between immunostimulatory lipids, inflammatory cells and foamy macrophages in extrinsic allergic alveolitis. Eur Respir J 1990; 3: 1128-1139.
47. Hull J, South M, Phelan P, Grimwood K. Surfactant composition in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 161-165.
48. Lesur O, Mancini NM, Janot C, Chabot F, Boitout A. Loss of lymphocyte modulatory control by surfactant lipid extracts from acute hypersensitivity pneumonitis: comparison with sarcoidosis and idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 1944-1949.
49. Low RB, Davis GS, Giancola MS. Biochemical analyses of bronchoalveolar lavage fluids of healthy human volunteer smokers and nonsmokers. Am Rev Respir Dis 1978; 118: 863-875.
50. Mancini NM, Bene MC, Gerard H, Chabot F. Early effects of short-time cigarette smoking on the human lung: a study of bronchoalveolar lavage fluids. Lung 1993; 171: 277-291.
51. McCormack FX, King TE, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 144: 160-166.
52. Nakos G, Pneumatikos J, Tsangaris I, Tellis C, Lekka M. Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 1997; 155: 945-951.
53. Phelps DS, Rose RM. Increased recovery of surfactant protein A in AIDS related pneumonia. Am Rev Respir Dis 1991; 143: 1072-1075.
54. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U. Surfactant abnormalities in patient with respiratory failure after multiple trauma. Am Rev Respir Dis 1989; 140: 1033-1039.
55. Pison U, Obertacke U, Brand M. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990; 30: 19-26.
56. Pison U, Obertacke U, Seeger W, Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Invest 1992; 22: 712-718.
57. Ramirez R, Harlan WR. Pulmonary alveolar proteinosis. Nature and origin of alveolar lipid. Am J Med 1968; 45: 502-512.
58. Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis 1988; 137: 585-591.
59. Rose RM, Catalano PJ, Koziel H, Furlong ST. Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 1994; 149: 332-338.
60. Schmekel B, Bos JH, Khan AR, Wohlfahrt B, Lachmann B, Wollner P. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers. Thorax 1992; 47: 603-608.
61. Sternberg RI, Whitsett JA, Hull WM. Pneumocystis carinii alters surfactant protein A concentration in bronchoalveolar lavage fluid. J Lab Clin Med 1995; 125: 462-469.
62. Van de Graaf E, Jansen HM, Lutter R, et al. Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med 1992; 120: 252-263.
63. Lesur O, Bernard A, Begin R. Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers. Chest 1996; 109: 467-474.
64. Ratjen F, Rehn B, Costabel U, Bruch J. Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Eur Respir J 1996; 9: 328-333.
65. Finley TN, Ladman AJ. Low yield of pulmonary surfactant in cigarette smokers. N Engl J Med 1972; 286: 223-227.
66. Cook W, Webb W. Surfactant in chronic smokers. Ann Thorac Surg 1966; 2: 327-333.
67. Hanrahan J, Sherman C, Bresnitz E, Emmons K, Mannino D. Cigarette smoking and health. Official statement of the American Thoracic Society. Am J Respir Crit Care Med 1996; 153: 861-865.
68. Hohlfeld J, Fabel H, Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J 1997; 10: 482-491.
69. Sahu S, Lynn WS. Lipid composition of airways secretion from patients with asthma and patients with cystic fibrosis. Am Rev Respir Dis 1977; 115: 233-239.
70. Kurashima K, Fujimura M, Matsuda T, Kobayashi T. Surface activity of sputum from acute asthmatic patients. Am J Respir Crit Care Med 1997; 155: 1254-1259.
71. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 1996; 75: 133-136.
72. Hohlfeld J, Tirayaki E, Hamm H, et al. Pulmonary surfactant activity is impaired in lung transplant recipients. Am J Respir Crit Care Med 1998; 158: 706-712.
73. Hohlfeld J, Tschom H, Tirayaki E, et al. Surfactant protein A (SP-A) alterations in bronchoalveolar lavage of lung transplant patients. Appl Cardiopulm Pathophysiol 1995; 5: 59-61.
74. Hoffmann AG, Lawrence MG, Ognibene F, Suffredini AF, Lipschick GY, Kovacs J. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992; 102: 1730-1736.
75. Downing J, Pasula R, Wright JR, Twigg H, Martin W. Surfactant protein A promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus. Proc Natl Acad Sci USA 1995; 92: 4848-4852.
76. Hallman M, Merrit TA, Ohjavuori M, Gluck L. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and relationship to severity of respiratory failure. Pediatr Res 1986; 20: 1228-1235.
77. Stevens PA, Schadow B, Bartholain S, Segerer H, Obladen M. Surfactant protein A in the course of respiratory distress syndrome. Eur J Pediatr 1992; 151: 596-600.
78. Griese M, Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152: 1050-1054.
79. Taieb J, Francoual J, Magny JF, Fraslon C, Massaoudi C. Surfactant associated protein A determination using a chemiluminescence system-application to tracheal aspirates from newborn. Clin Chim Acta 1995; 235: 229-234.
80. Morley CJ, Brown BD, Hill CM, Barson AJ, Davis JA. Surfactant abnormalities in babies dying from sudden infant death syndrome. Lancet 1982; 1: 1320-1322.
81. Hills BA, Masters IB, Vance JC, Hills YC. Abnormalities in surfactant in sudden infant death syndrome as a postmortem marker and possible test of risk. J Paediatr Child Health 1997; 33: 61-66.
82. Hamm H, Löhrs J, Guzman y Rotaeche J, Costabel U, Fabel H, Bartsch W. Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest 1994; 106: 1766-1770.
83. Cormier Y, Israel-Assayag E, Desmeules M, Lesur O. Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung. Thorax 1996; 51: 1210-1215.
84. Pracyk JB, Simonson SG, Young SL, Ohio AJ. Composition of lung lavage in pulmonary alveolar microlithiasis. Respiration 1996; 63: 254-260.
85. Hallman M, Maasilta P, Kivisaari L, Mattson K. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis 1990; 141: 998-1005.
86. Maasilta P, Hallman M, Taskinen E, Kivisaari L. Bronchoalveolar lavage fluid findings following radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993; 26: 117-123.
87. Puchmajerova J, Marsakova H, Novotny L. Prinos bronchoalveolarnich lavazi pro diagnostiku a lecbu opokavonych respiracnich onemecneni u deti. Czech Ped 1991; 46: 161-163.
88. Hohlfeld J, Ahlf K, Balke K, et al. Pulmonary surfactant function is impaired in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med 1997; 157: A446.
89. Lusuardi M, Capelli A, Carli S, Tacconi MT, Salmona M, Donner CF. Role of surfactant in chronic obstructive pulmonary disease: therapeutic implications. Respiration 1992; 59: 28-32.
90. Gilljam H, Andersson O, Ellin A, Robertson B, Strandvik B. Composition and surface properties of the bronchial lipids in adult patients with cystic fibrosis. Clin Chim Acta 1988; 176: 29-38.
91. Gilljam H, Strandvik B, Ellin A, Wiman LG. Increased mole fraction of arachidonic acid in bronchial phospholipids in patient with cystic fibrosis. Scand J Clin Lab Invest 1986; 46: 511-518.
92. Rudnik J, Hanicka M, Pawelek J, Zebrak J, Majewska-Zalewska H, Sowinska E. Pulmonary surfactant contents in bronchial secretion in children with chronic respiratory diseases estimated by physico-chemical methods. Z Erkrank Atemw 1983; 160: 44-47.
93. Gutkowski P, Rudnik J, Jaskiewicz J, Pawelek J, Lejman W, Hanicka M. Surface activity and chemical composition of bronchial washings in children. Bronchol Pneumol 1979; 29: 478-482.
94. Brogden KA. Changes in pulmonary surfactant during bacterial pneumonia. Antonie Van Leeuwenhoek 1991; 59: 215-223.
95. LeVine AM, Lotze A, Stanley S, et al. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996; 24: 1062-1067.
96. Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H. Changes in fatty acids in phospholipids of bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 1984; 30: 521-523.
97. Martin W, Downing J, Willams M, Pasula R, Twigg H, Wright JR. Role of surfactant protein A in the pathogenesis of tuberculosis in subjects with human immunodeficiency virus infection. Proc Assoc Am Physicians 1995; 107: 340-345.
98. Bersten A, Doyle IR, Davidson KG, Barr HA, Nicholas TE, Kermeen F. Surfactant composition reflects lung overinflation and arterial oxygenation in patients with acute lung injury. Eur Respir J 1998; 12: 301-308.
99. Petty TL, Reiss OK, Paul GW, Silvers GW, Elkins N. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis 1977; 115: 531-536.
100. Petty TL, Silvers GW, Paul GW, Stanford RE. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest 1979; 5: 571-579.
101. Stamme C, Leuwer M, Lührs J, et al. Alterations in pulmonary surfactant during the course of sepsis-induced ARDS predisposition. Appl Cardiopulm Pathophysiol 1997; 6: 223-232.
102. Shimura S, Masuda T, Takishima T, Shirato K. Surfactant apoprotein-A concentration in airway secretions for the detection of pulmonary oedema. Eur Respir J 1996; 9: 2525-2530.
103. Tanaka K, Kumon K, Yamamoto F. Respiratory care of pediatric patients requiring prolonged intubation after cardiac surgery. Crit Care Med 1986; 14: 617-619.
104. Komani H, Haworth SG. The effect of cardiopulmonary bypass on the lung. In: Jonas I, Elliot M, eds. Cardiopulmonary bypass in neonates, infants and young children. Oxford, Butterworth-Heinemann, 1994; pp. 242-262.
105. McGowan FX, Nido D, Kurland G. Cardiopulmonary bypass significantly reduces surfactant activity in children. J Thorac Cardiovasc Surg 1993; 106: 968-977.
106. Griese M, Wilnhammer C, Jansen S, Rinker C. Cardiopulmonary bypass reduces surfactant activity in infants. J Thoracic Cardiovasc Surg 1999; in press.
107. Marcatili S, Guarino C, Giannattasio A. Alterations of the endoalveolar surfactant after surgery with extracorporeal circulation. Respiration 1990; 57: 233-238.
108. Lotze A, Whitsett JA, Kammermann L, Ritter M. Surfactant protein A concentrations in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation. J Pediatr 1990; 116: 435-440.
109. Avery ME, Mead RJ. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517-523.
110. Adams FH, Fujiwara T, Emmanouilides CG, Raehiae E. Lung phospholipids of human fetuses and infants with and without hyaline membrane disease. J Pediatr 1970; 833: 833-841.
111. Gruenwald P, Johnson RP, Hustead RF, Clements JA. Correlation of mechanical properties of infant lungs with surface activity of extracts. Proc Soc Exp Biol Med 1962; 109: 369-371.
112. Balis JU, Delivoria M, Conen PE. Maturation of postnatal human lung and the idiopathic respiratory distress syndrome. Lab Invest 1966; 15: 530-546.
113. Brumley GW, Hodson WA, Avery ME. Lung phospholipids and surface tension correlations in infants with and without hyaline membrane disease and in adults. Pediatrics 1967; 40: 13-19.
114. Reynolds ER, Orzalesi MM, Motoyama EK, Craig JM, Cook CD. Surface properties of saline extracts from lungs of newborn infants. Acta Paediatr Scand 1965; 54: 511-518.
115. Reynolds ER, Roberton NC, Wigglesworth JS. Hyaline membrane disease, respiratory distress, and surfactant deficiency. Pediatrics 1968; 42: 758-768.
116. Gandy G, Bradbrooke JG, Naidodo BT, Gairdner D. Comparison of methods for evaluating surface properties of lung in perinatal period. Arch Dis Child 1968; 43:8-16.
117. Gluck L, Kulovich MV, Eidelman AI, Cordero L, Khazin AF. Biochemical development of surface activity in mammalian lung. IV. Pulmonary lecithin synthesis in the human fetus and newborn and etiology of the respiratory distress syndrome. Pediatr Res 1972; 6: 81-99.
118. Hill CM, Brown BD, Morley CJ, Davis JA, Barson AJ. Pulmonary surfactant. I. In immature and mature babies. Early Hum Dev 1988; 16: 143-151.
119. Markgraf LR, Paciga JE, Balis JU. Surfactant-associated glycoproteins accumulate in alveolar cells and secretions during reparative stage of hyaline membrane disease. Hum Pathol 1990; 21: 392-396.
120. Ikegami M, Jacobs H, Jobe A. Surfactant function in respiratory distress syndrome. J Pediatr 1983; 102: 443-447.
121. Griese M, Westerburg B. Surfactant function in neonates with respiratory distress syndrome. Respiration 1998; 65: 136-142.
122. Obladen M. Factors influencing surfactant composition in the newborn infant. Eur J Pediatr 1978; 128: 129-143.
123. Obladen M, Merritt A, Gluck L. Acceleration of pulmonary surfactant maturation in stressed pregnancies: a study of neonatal lung effluent. Am J Obstet Gynecol 1979; 135: 1079-1085.
124. Shelley S, Kovacevic M, Paciga JE, Balis JU. Sequential changes of surfactant phosphatidylcholine in hyaline-membrane disease of the newborn. N Engl J Med 1979; 300: 112-116.
125. Motoyama EK, Namba Y, Rooney SA. Phosphatidylcholine content and fatty acid composition of tracheal and gastric liquids from premature and full-term newborn infants. Clin Chim Acta 1976; 70: 449-454.
126. Asthon MR, Postle AD, Hall MA, Smith SL, Kelly FJ, Normand IS. Phosphatidylcholine composition of endotracheal tube aspirates of neonates and subsequent respiratory disease. Arch Dis Child 1992; 67: 378-382.
127. Bourbon JR, Francoual J, Magny JF, Lindenbaum A, Leluc R, Dehan M. Changes in phospholipid composition of tracheal aspirates from newborn with hyaline membrane disease or transient tachypnoea. Clin Chim Acta 1990; 189: 87-94.
128. James DK, Chiswick ML, Harkes A, Williams M, Hallworth J. Non-specificity of surfactant deficiency in neonatal respiratory disorders. BMJ 1984; 288: 1635-1638.
129. Hallman M. Lung surfactant in respiratory distress syndrome. Acta Anaesthesiol Scand 1991; 35: 15-21.
130. Hallman M, Merritt TA, Kari A, Bry K. Factors affecting surfactant responsiveness. Ann Med 1991; 23: 693-698.
131. Kari MA, Raivio KO, Venge P, Hallmann M. Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens. Pediatr Res 1994; 36: 387-393.
132. Wang JY, Yeh TY, Lin YC, Miyamura K, Holmskov U, Reid KM. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax 1996; 51: 907-913.
133. Hallman M, Merrit TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Am Rev Respir Dis 1991; 144: 1376-1384.
134. Moya FR, Montes HF, Thomas VL, Mouzinho AM, Smith JF, Rosenfeld CR. Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150: 1672-1677.
135. Chida S, Phelps DS, Cordle C, Soll R, Floras J, Taeusch HW. Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy. Am Rev Respir Dis 1988; 137: 943-947.
136. Ijsselstijn H, Zimmermann L, Bunt J, de Jongste J, Tibboel D. Prospective evaluation of surfactant composition in bronchoalveolar lavage fluid of infants with congenital diaphragmatic hernia and of age-matched controls. Crit Care Med 1998; 26: 573-580.
137. Moulton SL, Krous HJ, Merritt A, Odell RM. Congenital pulmonary alveolar proteinosis: failure of treatment with extracorporeal life support. J Pediatr 1992; 120: 297-302.
138. Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief-report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328: 406-410.
139. Hamvas A, Cole FS, deMello DE, Moxley M. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994; 125: 356-361.
140. de Mello DE, Nogee LM, Heymann S, Kraus HF. Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 1994; 125: 43-50.
141. Hamvas A, Nogee LM, Mallory GB, Spray TL. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997; 130: 231-239.
142. Klein J, Thompson M, Snyder J, et al. Transient surfactant protein B deficiency in a term infant with severe respiratory failure. J Pediatr 1998; 132: 244-248.
143. Griese M, Westerburg B, Potz C, Dietrich P. Respiratory support, surface activity and protein content during nosocomial infection in preterm neonates. Biol Neonate 1996; 70: 271-279.
144. James D, Berry J, Fleming P, Hathaway M. Surfactant abnormality and the sudden infant death syndrome - a primary or secondary phenomenon? Arch Dis Child 1990; 65: 774-778.
145. Morley CJ, Davies RJ, Hill CM. Alveoli and abnormal surfactant. Lancet 1985; 1: 1329-1330.
146. Masters IB, Vance J, Hills BA. Surfactant abnormalities in ALTE and SIDS. Arch Dis Child 1994; 71: 501-505.
147. Hills BA, Masters IB, O'Duffy JF. Abnormalities of surfactant in children with recurrent cyanotic episodes. Lancet 1992; 339: 1323-1324.
148. Fagan DG, Milner AD. Pressure volume characteristerics of the lung in sudden infant death syndrome. Arch Dis Child 1985; 60: 471-485.
149. Floros J, Kala P. Surfactant proteins: molecular genetics of neonatal pulmonary diseases. Annu Rev Physiol 1998; 60: 365-384.
150. McCormack FX, King TE, Bucher BL, Nielsen L. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152: 751-759.
151. Guzman J, Wang Y, Kalaycioglu O, et al. Increased surfactant protein A content in human alveolar macrophages in hypersensitivity pneumonitis. Acta Cytol 1992; 36: 668-673.
152. Stahlman MT, Gray ME, Ross GF, et al. Human surfactant protein-A contains blood group A antigenic determinants. Pediatr Res 1992; 31: 364-371.
153. Akino T, Okano G, Ohno K. Alveolar phospholipids in pulmonary alveolar proteinosis. Tohoku J Exp Med 1978; 126: 51-62.
154. Onodera T, Nakamura M, Sato T, Akino T. Biochemical characterization of pulmonary washings of patients with alveolar proteinosis, interstitial pneumonitis and alveolar cell carcinoma. Tohoku J Exp Med 1983; 139: 245-263.
155. Sahu S, DiAugustine RP, Lynn WS. Lipids found in pulmonary lavage of patients with alveolar proteinosis and in rabbit lung lamellar organelles. Am Rev Respir Dis 1976; 114: 177-185.
156. Hattori A, Kuroki Y, Katoh T, Takahashi H. Surfactant protein A accumulating in the alveoli of patients with pulmonary alveolar proteinosis: oligomeric structure and interaction with lipids. Am J Respir Cell Mol Biol 1996; 14: 608-619.
157. Hattori A, Kuroki Y, Takahashi H, Sohma H. Immunoglobulin G is associated with surfactant protein A aggregate isolated from patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1997; 155: 1785-1788.
158. Suzuki Y, Shen HQ, Sato A, Nagai S. Analysis of fused-membrane structures in bronchoalveolar lavage fluid from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 1995; 12: 238-249.
159. Masuda T, Shimura S, Sasaki H, Takishima T. Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet 1991; 337: 580-582.
160. Paul K, Müller KM, Oppermann HC, Nützenadel W. Pulmonary alveolar lipoproteinosis in a seven-year-old girl. Acta Paediatr Scand 1991; 80: 477-481.
161. Mahut B, de Blic J, Bourgeois ML, Beringer A. Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis. Pediatr Pulmonol 1992; 13: 50-53.
162. Mahut B, Delcourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97: 117-122.
163. Ladeb S, Fleury-Feith J, Escudier E. Secondary alveolar proteinosis in cancer patients. Support Care Cancer 1996; 4: 420-426.
164. Tchou-Wong KM, Harkin TJ, Chi C, Bodkin M. GM-CSF gene expression is normal but protein release is absent in a patient with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1997; 156: 1999-2002.
165. Haagsman HP. Toxicological aspects of the surfactant system. In: Robertson B, van Golde L, Batenburg JJ, eds. Pulmonary surfactant: from molecular biology to clinical practice. Amsterdam, Elsevier, 1992; 705-734.
166. Foucher P, Biour M, Blayac J, et al. Drugs that may injure the respiratory system. Eur Respir J 1997; 10: 265-279.
167. Nicolet-Chatelain G, Prevost M, Escamilla R, Migueres J. Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. Chest 1991; 99: 353-369.
168. Rossi G, Balbi B, Benatti U, et al. Changes in pulmonary surfactant composition following MACC chemotherapy for lung carcinoma. Eur J Respir Dis 1987; 71: 400-409.
169. Steinberg F, Rehn B, Kraus R, et al. Activity testing of alveolar macrophages and changes in surfactant phospholipids after irradiation in bronchoalveolar lavage: experimental and clinical data. Environ Health Perspect 1992; 97: 171-175.
170. Kurashima K, Ogawa H, Fujimura K, Matsuda T, Kobayashi T. A pilot study of surfactant inhalation for the treatment of asthmatic attack. J Allergol 1991; 2: 160-163.
171. Oetomo SB, Dorrepaal C, Bos H, et al. Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med 1996; 153: 1148-1152.
172. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 1998; 42: 805-810.
173. Griese M, Bufler P, Teller J, Reinhardt D. Nebulization of a bovine surfactant in cystic fibrosis: a pilot study. Eur Respir J 1997; 10: 1989-1997.
174. Anzueto A, Jubran A, Ohar JA, Pipuette C, Rennard S. Effects of aerosolized surfactant in patient with stable chronic bronchitis. JMS 1997; 278: 1426-1431.
175. Mikawa K, Maekawa N, Nishina K, Takao Y, Yuka H. Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur Respir J 1993; 6: 1563-1566.
176. Marriage SC. Use of natural surfactant in an HIV-infected infant with Pneumocystis carinii pneumonia. Intensive Care Med 1996; 22: 611-612.
177. Creery W, Hashmi A, Hutchinson J, Singh R. Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Ped Pulmonol 1997; 24: 370-373.
178. Vos GD, Rijtema MN, Blanco CE. Treatment of respiratory failure due to respiratory syncytial virus pneumonia with natural surfactant. Pediatr Pulmonol 1996; 22: 412-415.
179. Pallua N, Warbanow K, Machens HG, Poets C, Berger A. Intrabronchiale Surfactantapplikation bei inhalationstraumatisierten Schwerbrandverletzten mit ARDS. Unfallchirurgie 1997; 100: 363-370.
180. Richman PS, Spragg RG, Robertson B, Merrit TA. The adult respiratory distress syndrome: first trials with surfactant replacement. Eur Respir J 1989; 2: 109-111.
181. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334: 1417-1421.
182. Heikinheimo M, Hynynen M, Rautiainen P, Andersson S. Successful treatment of ARDS with two doses of synthetic surfactant. Chest 1994; 105: 1263-1264.
183. Gregory TJ, Steinberg KP, Spragg R, Gadek JE. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155: 1309-1315.
184. Walmrath D, Günther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154: 54-62.
185. Spragg R, Gillard N, Richman P, et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195-202.
186. Haslam PL, Hughes DA, Naughton PD, Baker CS. Surfactant replacement therapy in late-stage adult respiratory distress syndrome. Lancet 1994; 343: 1009-1011.
187. Müller JC, Schaible T, Tegtmeyer FK, Gortner L. Surfactantbehandlung des respiratorischen Versagens im Kindesalter jenseits der Neugeborenenperiode. Monatsschr Kinderhkd 1995; 143: 685-690.
188. Buheitel G, Scharf J, Harms D. Erfahrungen mit der Surfactanttherapie des adulten Atemnotsyndroms (ARDS). Monatsschr Kinderhkd 1992; 140: 629-632.
189. Harms K, Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 1994; 61: 348-352.
190. Feickert H, Sasse M, Kayser C. Surfactant therapy in acute respiratory distress syndrome (ARDS) of children. Appl Cardiopulm Pathophysiol 1998; 7: 9-16.
191. Fujiwara T, Konishi M, Chida S, Okuyama K. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990; 86: 753-764.
192. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 1995; 67 (Suppl. 1): 32-47.
193. Soll RF. Surfactant therapy in the USA: trials and current routines. Biol Neonate 1997; 71 (Suppl. 1): 1-7.
194. Halliday H, Speer C, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative surfactant study group. Eur J Pediatr 1996; 155: 1047-1051.
195. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97: 48-52.
196. Fetter WF, Baerts W, Bos AP, Lingen V. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr Scand 1995; 84: 14-16.
197. Herting E, Harms K, Gefeller O, Pralle L. Surfactant treatment of respiratory failure in neonatal group B streptococcal infections: first results of a European retrospective trial. Biol Neonate 1997; 71: 67-68.
198. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101-107.
199. Gortner L, Pohlandt F, Bartmann P. Wirkung eines bovinen Surfactant bei sehr kleinen Fruehgeborenen mit konnataler Pneumonie. Monatsschr Kinderhkd 1990; 138: 274-278.
200. Lotze A, Mitchell B, Bulas D, Zola E, Shalwitz R, Gunkel J. Survanta in term Infants Study Group. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 1998; 132: 40-46.
201. Bae C, Jang C, Chung S, et al. Exogenous pulmonary surfactant replacement therapy in a neonate with pulmonary hypoplasia accompanying congenital diaphragmatic hernia - a case report. J Korean Med Sci 1996; 11: 265-270.
202. Lotze A, Knight G, Anderson K, et al. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 1994; 29: 407-412.
203. Glick P, Leach C, Besner G, Egan E. Pathophysiology of congenital diaphragmatic hernia. III: Exogenous surfactant therapy for the high risk neonate with CDH. J Pediatr Surg 1992; 27: 866-869.
204. Macnaughton PD, Evans TW. The effect of exogenous surfactant therapy on lung function following cardiopulmonary bypass. Chest 1994; 105: 421-425.
205. DoCampo J, Bertranou EG, De Lorenzi A, Hager AA. Nebulised exogenous natural surfactant after cardiac surgery. Lancet 1994; 343: 482.
206. Strüber M, Cremer J, Harringer W, Hirt S, Costard-Jäckle A, Haverich A. Nebulized synthetic surfactant in reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg 1995; 110: 563-564.
207. McBrien M, Katumba J, Mukhtar A. Artificial surfactant in the treatment of near drowning. Lancet 1993; 342: 1485-1486.
208. Suzuki H, Ohta T, Iwata K, Yamaguchi K. Surfactant therapy for respiratory failure due to near drowning. Eur J Pediatr 1996; 155: 383-384.
209. Häfner D, Germann P, Hauschke D. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am J Respir Crit Care Med 1998; 158: 270-278.
210. Cochrane CG, Revak S, Merritt TA, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404-410.
211. McLean L, Lewis J. Biomimetic pulmonary surfactants. Life Sci 1995; 56: 363-378.
212. Sun B, Curstedt T, Lindgren G, et al. Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Respir J 1997; 10: 1967-1974.
213. Mason R, Greene K, Voelker DR. Surfactant protein A and surfactant protein D in health and disease. Am J Physiol 1998; 275: L1-L13.
214. Hickling T, Malhotra R, Sim RB. Human lung surfactant protein A exists in several different oligomeric states: oligomer size distribution varies between patient groups. Mol Med 1998; 4: 266-275.
215. Wang JY, Shieh C, You P, Lei H, Reid K. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma. Am J Respir Crit Care Med 1998; 158: 510-518.
216. Israel-Assayag E, Cormier Y. Surfactant modifies the lymphoproliferative activity of macrophages in hypersensitivity pneumonitis. Am J Physiol 1997; 273: L1258-L1264.